Acceleron To Receive $7 Mln Milestone Payment From Celgene - Quick Facts

(RTTNews) - Acceleron Pharma Inc. (XLRN), a clinical stage biopharmaceutical company, Wednesday said its collaboration partner, Celgene, has initiated a phase 2 clinical trial of sotatercept in patients with end stage renal disease on hemodialysis.

Sotatercept is a novel and first-in-class activin type IIA receptor fusion protein that acts during late-stage erythropoiesis to increase the production of mature red blood cells into circulation.

Acceleron will receive a $7 million milestone payment from Celgene for the achievement of this event and is also eligible to receive future development, regulatory and commercial milestones of up to $360 million for the sotatercept program.